INGR1D2

  • Research type

    Research Study

  • Full title

    Identification of infants with increased type 1 diabetes risk for enrolment into primary prevention trials

  • IRAS ID

    298196

  • Contact name

    Stephen Robson

  • Contact email

    s.c.robson@ncl.ac.uk

  • Sponsor organisation

    The Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    3 years, 0 months, 0 days

  • Research summary

    Primary prevention of common chronic disease is a major public health goal. Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. The clinical onset of type 1 diabetes is preceded by a phase where the child is well but has multiple beta-cell auto-antibodies in their blood against insulin-producing beta cells,which are present in the pancreas. Neonates and infants who are at increased risk of developing multiple beta-cell auto-antibodies and type 1 diabetes can now be identified using genetic markers. This provides an opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.

    The objective of this study is to determine the percentage of children with genetic markers putting them at increased risk of developing type 1 diabetes, and to offer the opportunity for these children to be enrolled into phase II b primary prevention trials.

  • REC name

    North East - Newcastle & North Tyneside 1 Research Ethics Committee

  • REC reference

    21/NE/0161

  • Date of REC Opinion

    14 Oct 2021

  • REC opinion

    Further Information Favourable Opinion